Agios Pharmaceuticals, Inc. research snapshot
AGIO AI stock analysis currently reads Agios Pharmaceuticals as a rare-disease biotech that is commercializing AQVESME (mitapivat) in thalassemia while awaiting an FDA decision for mitapivat in sickle cell disease by November 1, 2026. At the August 4, 2026 cutoff, the quoted price was $30.54, market capitalization was about $1.82 billion, and the key development was the July 21 decision to stop tebapivat in SCD after a Phase 2 miss, which cut the stock from the low-$40s into the $30s. This is informational research and not investment advice.
Current price
$30.54
Market cap
$1.82 billion
AI score
48 / 100
Rating
Pipeline-driven biotech navigating a narrowed SCD franchise
Trend status
Downtrend below 50-day average ahead of November 1 PDUFA
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Agios sells mitapivat (PYRUKYND for PK deficiency and European thalassemia, AQVESME for U.S. thalassemia), a PK activator with roughly 92% gross margin. Q2 2026 net revenue grew to $44.7M, and the business model is product revenue plus a diversified late-stage pipeline. | Medium |
| Moat | Regulatory exclusivity, IP protection around PK activation, and a specialized rare disease commercial infrastructure support the position. The July tebapivat Phase 2 miss shows PK activation is hard to differentiate in SCD, so mitapivat must prove a label edge over competitor PK activators. | Medium |
| Management | CEO Brian Goff (ex-Alexion) brings rare disease commercial experience, visible in the strong AQVESME U.S. launch. Management showed discipline by stopping tebapivat in both LR-MDS and SCD rather than extending development, and it diversified the pipeline by licensing cevidoplenib for ITP. | Medium |
| Financial trend | Revenue is accelerating, with TTM revenue near $98.3M and Q2 2026 net revenue of $44.7M versus $12.5M a year earlier. The company remains pre-profit with a TTM net loss near $411M, and cash, cash equivalents, and marketable securities were $964.8M as of June 30, 2026. | Medium |
| Valuation | At about 18.5x TTM revenue with a net cash position near $0.93B, enterprise value is roughly $0.89B and EV/Sales is about 9. The market prices in SCD approval and continued AQVESME growth; margin of safety is thin if the FDA decision is unfavorable. | Medium-low |
| Technical trend | The stock trades at $30.54, below the 50-day average near $34.23 and just under the 200-day average near $31.58, with RSI near 32. It fell from the July catalyst highs around $46 and the 52-week range is $22.24 to $46.00. Confirm moving averages, support, resistance, and volume with live data before acting. | Medium |
| Risk level | The thesis can fail if the FDA rejects or delays mitapivat for SCD, if AQVESME or PYRUKYND adoption disappoints, if cash burn requires dilutive financing, or if competitor SCD therapies including other PK activators take share. The tebapivat stoppage already reduced pipeline breadth. | Medium-high |
| AI confidence | Medium data confidence for qualitative mapping and verified financials. Lower confidence for forward binary outcomes that depend on the November 1, 2026 FDA decision and on post-launch commercial data. | Medium data confidence |
| Investment certainty | Low to medium certainty because biotech catalyst outcomes are inherently binary and the page provides a framework, not personalized buy or sell instructions. | Low to medium |
AGIO AI stock forecast
The AGIO AI stock forecast uses scenario ranges around the $30.54 quote rather than a point target. The near-term path depends primarily on the FDA PDUFA date of November 1, 2026 for mitapivat in sickle cell disease and on AQVESME sales traction. The bullish case requires SCD approval plus a strong AQVESME trajectory; the base case assumes approval but measured SCD uptake; the bearish case assumes a negative FDA decision, a restricted label, or renewed commercial and financing pressure.
$45.00 to $55.00
More likely if the FDA approves mitapivat for SCD around the November 1, 2026 PDUFA date with a competitive label, if AQVESME thalassemia prescriptions keep growing from the 442 cumulative scripts at June 30, and if cevidoplenib or AG-236 add pipeline value. Sell-side targets cluster near this range, with Citi at $52 and H.C. Wainwright at $55.
$32.00 to $45.00
More likely if the FDA approves mitapivat for SCD with labeling restrictions or if adoption builds gradually, while AQVESME and PYRUKYND revenue keep compounding. The stock would need to reclaim the 50-day average near $34.23 and hold above it to stabilize this range.
$22.00 to $30.00
More likely if the FDA issues a Complete Response Letter or extends review, if SCD or thalassemia commercial metrics disappoint, if the cash burn forces dilutive equity financing, or if competing SCD therapies including other PK activators gain share. The low end approaches the 52-week low of $22.24.
AGIO AI technical analysis
AGIO AI technical analysis starts from the $30.54 quote. The stock dropped from its July highs near $46 after the July 21 tebapivat SCD Phase 2 miss and now trades below both its 50-day average near $34.23 and its 200-day average near $31.58, with RSI near 32. Because this static page does not fetch request-time chart data, moving averages and live momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $30.54 | Close on August 3, 2026, used as the quote for this page as of the August 4, 2026 data cutoff. |
| Near support | $28.50 to $29.50 | Recent trading lows around the early August pullback zone. A daily close below this band would point toward a test of the 52-week low near $22.24. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $34.23 to $37.00 | The 50-day moving average near $34.23 is the first resistance, with a thicker supply zone up to $37.00. A reclaim and hold above the 50-day average on above-average volume would be the first momentum improvement signal. |
| 200-day moving average | $31.58 | The price sits just below this line, so the stock is testing its longer-term trend level. Use live chart data to confirm whether it holds or breaks. |
| Momentum | Short-term downtrend, RSI near 32 | RSI near 32 is close to oversold after the tebapivat-driven repricing. A low RSI can stabilize, but trend confirmation requires price reclaiming the 50-day average. |
| Volume | Elevated on news days | Volume spiked around the July 21 tebapivat news and the July 30 earnings report. Sustained above-average volume near resistance increases the chance of a breakout or a continuation lower. |
| Volatility | High monitoring priority | Biotech binary event risk means wide daily swings are normal. Position sizing must account for potential 10-20% moves around FDA news and data readouts. |
| Invalidation | Close below $28.50 | A decisive close below the support zone would weaken the setup and suggest a test of the 52-week low near $22.24 is more likely. |
AGIO AI trading strategy
The AGIO AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh filings or news checks, especially around the November 1 PDUFA date and quarterly launches.
Wait for AGIO to reclaim and hold the 50-day average near $34.23 with above-average volume that confirms renewed buyer demand before treating the downtrend as reversing.
A close back below the 50-day average or below $28.50 support should invalidate the setup. Reduce position before the FDA decision to manage binary event risk.
If AGIO stabilizes in the $28.50 to $30.50 zone near the 200-day average without a fundamental thesis break, compare price action with AQVESME prescription data, pipeline updates, and the FDA timeline.
Do not average down without a predefined maximum loss and a fresh assessment of the risk-reward around the PDUFA date, given the stock already repriced the tebapivat failure.
Track the evidence that matters most: FDA Advisory Committee meeting date and briefing documents if scheduled, the PDUFA decision on November 1, 2026 for mitapivat in SCD, AQVESME prescription trends, and cash runway updates.
Reduce confidence when price moves are driven by speculation without new fundamental evidence. Consider defining position size based on the maximum loss you can tolerate from a negative FDA decision.
Investment research summary
Agios develops and commercializes mitapivat, a pyruvate kinase activator sold as PYRUKYND (PK deficiency and European thalassemia) and AQVESME (U.S. thalassemia). The company sold its oncology business to Servier in 2020 to focus on rare hematologic diseases, and Q2 2026 net revenue of $44.7M shows the thalassemia launch is gaining traction.
Regulatory exclusivity and IP protection for PK activation, first-in-class positioning in PK deficiency, a specialized rare disease commercial infrastructure, and an approved brand in thalassemia. The July tebapivat Phase 2 miss showed differentiation is hard, so the moat depends on mitapivat winning a durable SCD label and on AQVESME execution.
The thesis can fail if the FDA does not approve mitapivat for SCD, if post-marketing safety issues emerge, if AQVESME or PYRUKYND growth stalls, if competitors develop superior oral SCD therapies, if pipeline candidates such as AG-236 or cevidoplenib disappoint, or if cash burn forces dilutive financing below current prices.
CEO Brian Goff (from Alexion, a successful rare disease commercial story) brings relevant experience, and the AQVESME U.S. launch is executing well. Management showed capital discipline by stopping tebapivat in both LR-MDS and SCD and by licensing cevidoplenib for ITP instead of stretching internal programs.
Rare disease genetics is a secular growth area in biopharma. SCD affects roughly 100,000 people in the U.S. with significant unmet need, and gene therapies face access and durability questions, leaving room for oral small molecules. The thalassemia market also expanded with the 2026 European approval of PYRUKYND.
At about $1.82B market cap with roughly $0.93B net cash, enterprise value is near $0.89B. Current revenue of about $98.3M TTM does not support the valuation on its own; the market prices in SCD approval and continued AQVESME growth. Margin of safety is thin if the FDA decision is negative, and the stock already repriced part of the pipeline risk in July.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| AGIO price | $30.54 | StockAnalysis.com quote (CBOE real-time data), August 3, 2026 close | August 4, 2026 |
| Market capitalization | $1.82 billion, verified as $30.54 x 59.70M shares using financial_rigor.py (deviation 0.18%) | financial_rigor.py market cap verification and StockAnalysis.com | August 4, 2026 |
| Shares outstanding | 59.70 million | StockAnalysis.com and company Q2 2026 filings | August 4, 2026 |
| Cash, cash equivalents and marketable securities | $964.8 million as of June 30, 2026 (cross-validated across the company Q2 2026 press release and news coverage) | Agios Q2 2026 financial results press release (GlobeNewswire) | August 4, 2026 |
| Revenue TTM (June 2026) | $98.3 million, cross-validated from reported figures using financial_rigor.py (H1 2026 of $65.5M plus implied H2 2025) | StockAnalysis.com financials (S&P Global/Fiscal.ai data) | August 4, 2026 |
| Q2 2026 net revenue | $44.7 million, cross-validated across GlobeNewswire and TheFly within 0.01% deviation | Agios Q2 2026 financial results press release (GlobeNewswire) | August 4, 2026 |
| Net income TTM (June 2026) | -$411.3 million | StockAnalysis.com financials (S&P Global/Fiscal.ai data) | August 4, 2026 |
| AQVESME cumulative U.S. prescriptions | 442 prescriptions written by REMS-certified physicians as of June 30, 2026 | Agios Q2 2026 financial results press release (GlobeNewswire) | August 4, 2026 |
This AGIO AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 4, 2026, may be incomplete, and can be wrong if new filings, FDA decisions, clinical data, competitive events, market prices, or macro conditions change. Biotech investments carry binary event risk, and this stock repriced sharply in July 2026 after a pipeline setback.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
